Convexity Labs

CCXI

Convexity Analyst · CCXI
low confidenceTactical · no named thesis
Generated Jun 21, 2026

ANALYST NOTE: CCXI (Churchill Capital Corp XI) Date: 2026-06-12 Current Price: $10.22

1. Structural Readiness

  • State: Context-Only.
  • Conservative Entry: Not applicable (Breakout has not fired).
  • Aggressive/Pre-Breakout Entry: N/A (Current price is $10.22; entry is contingent on a confirmed breakout above the resistance structure).
  • Breakout Level: Pending confirmation above the immediate resistance structure (typically the $11.50 warrant exercise price or the $10.00 trust floor breakout).
  • Current Price: $10.22.
  • Extension: N/A (No confirmed breakout to measure extension from).
  • ATR Context: Current ATR is 4.5% (High). This indicates elevated volatility, which is typical for SPACs awaiting deal announcements. The ATR-at-breakout is not yet defined as the breakout has not occurred.

2. Thesis Layer

  • Thesis Classification: TACTICAL / SETUP-LED.
  • Macro Thesis: None. There is no named secular thesis or macroeconomic tailwind attached to this specific vehicle as of 2026-06-12.
  • Judgment Criteria: The investment case rests entirely on the structural quality of the SPAC setup (trust value, management track record) and the probability of a successful Business Combination. It is not a play on a specific industry secular trend but a play on the execution of the merger process itself.

3. The Business

  • Entity Type: Churchill Capital Corp XI is a Cayman Islands exempted company incorporated on June 4, 2025, for the specific purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses that have not yet been identified as of the latest filings.
  • Business Model: The company operates as a "blank check" vehicle. It holds cash in a Trust Account derived from its Initial Public Offering (IPO) and seeks to acquire a private operating company to take public.
  • Capital Structure & Funds:
  • As of December 31, 2025, the company held $414,549,783 in funds available for a Business Combination (before redemptions, permitted withdrawals, taxes, or deferred fees).
  • The IPO was consummated on December 18, 2025, consisting of 41,400,000 Public Units (including 5,400,000 Option Units).
  • Each Public Unit consists of one Public Share and one-tenth of one Public Warrant.
  • Each whole Public Warrant entitles the holder to purchase one Class A Ordinary Share for $11.50 per share.
  • Management Expectations: Management and M. Klein Company (an affiliate of the Sponsor) state they are "well positioned to identify and execute attractive Business Combination opportunities." Their stated objective is to generate attractive returns by selecting a high-quality target at an attractive valuation and improving operational performance post-acquisition.
  • Regulatory Constraint: To maintain Nasdaq listing, the company must complete a Business Combination with an aggregate fair market value of at least 80% of the assets held in the Trust Account (excluding Deferred Fee and taxes) at the time of the definitive agreement.

4. Archetype and Conviction

  • Archetype: Quality Compounder (Pre-Deal).
  • *Fit:* This classification is applied based on the structural integrity of the trust account and the stated management mandate to select high-quality targets. However, this is a "potential" compounder; the compounding has not yet begun as the target is unidentified.
  • Valuation Context:
  • The current price of $10.22 trades near the typical SPAC IPO price floor ($10.00).
  • The Trust Account value per share is approximately $10.01 ($414.5M / 41.4M units), implying the stock is trading at a slight premium to the trust value, likely reflecting the time value of the warrants and the market's expectation of a deal.
  • The Warrant Strike Price is $11.50, providing a structural ceiling for the equity value in the near term unless a significant deal premium is announced.
  • Conviction Stack:
  • Thesis Strength: Low (No specific target or sector identified).
  • Evidence Quality: Moderate (Clear trust balance and regulatory constraints defined in filings).
  • Structural Quality: High (80% test requirement ensures deal size is material; trust account is intact).
  • Setup Readiness: Partial (Forming coil; waiting for catalyst).
  • Rerating Potential: High *if* a deal is announced with a target trading at a discount to the implied post-merger valuation, but zero if the deal fails or is delayed indefinitely.
  • ATR Analysis: The current ATR of 4.5% (High) suggests the market is pricing in binary event risk (deal vs. no deal). This volatility is consistent with the "Forming" state where the catalyst is imminent but unknown.

5. Invalidations, Strengths, and Gaps

  • What Would Invalidate:
  • A formal announcement that the company has failed to identify a target within the statutory deadline (typically 24 months from IPO, though specific dates depend on the charter).
  • Significant redemptions that drop the trust value below the 80% threshold required for a deal, forcing a liquidation.
  • What Would Strengthen:
  • Announcement of a definitive agreement with a target business.
  • Confirmation that the target's fair market value meets or exceeds the 80% trust asset threshold.
  • Management commentary confirming the target is in a high-growth sector with strong unit economics.
  • Gaps in Evidence:
  • Target Identity: The single most critical missing piece of evidence is the identity of the target business. As of 2026-06-12, the target is "not yet identified."
  • Deal Terms: No information exists on the valuation, deal structure, or PIPE (Private Investment in Public Equity) size.
  • Management Track Record: While M. Klein Company is mentioned, specific historical success rates of this specific SPAC team in the current market environment are not detailed in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: low Key evidence: Trust account holds $414.5M with no redemptions reported; 80% fair market value test requirement ensures deal materiality; Management explicitly states target is not yet identified. Key risks: Target identification failure leading to liquidation; significant redemptions eroding trust value below 80% threshold; current price trading near trust floor with no deal premium. Sizing hint: Position size should be minimal, reflecting binary event risk and lack of specific thesis. Expected path: Management continues search for target; price likely remains range-bound near $10.00-$11.50 until definitive agreement is announced. Expected horizon: 6 to 18 months from event date, contingent on deal timeline. Failure mode to watch: A close below $10.00 indicating market pricing in liquidation or a formal announcement of deadline extension failure.

Loading chart...
Exhibit 1: CCXI daily candlestick — no active setup overlay.

Source-backed evidence anchors and catalysts land once Convexity finishes coverage for CCXI.

Core assumptions for this name haven't been articulated yet — they land alongside the rerating thesis.

Value picture unavailable — no financial spine on file for CCXI.

Layer B fundamentals snapshot not yet available. Highlights land once Convexity finishes the classification.

Coverage: